Cargando…

Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer

INTRODUCTION: Programmed cell death ligand-1 (PD-L1) expression is a promising biomarker for identifying treatment related to non-small cell lung cancer (NSCLC). Automated image analysis served as an aided PD-L1 scoring tool for pathologists to reduce inter- and intrareader variability. We developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Boju, Kang, Yuxin, Jin, Yan, Yang, Lin, Zheng, Yushuang, Cui, Lei, Sun, Jian, Feng, Jun, Li, Yuan, Guo, Lingchuan, Liang, Zhiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185941/
https://www.ncbi.nlm.nih.gov/pubmed/34098964
http://dx.doi.org/10.1186/s12967-021-02898-z
_version_ 1783704860472901632
author Pan, Boju
Kang, Yuxin
Jin, Yan
Yang, Lin
Zheng, Yushuang
Cui, Lei
Sun, Jian
Feng, Jun
Li, Yuan
Guo, Lingchuan
Liang, Zhiyong
author_facet Pan, Boju
Kang, Yuxin
Jin, Yan
Yang, Lin
Zheng, Yushuang
Cui, Lei
Sun, Jian
Feng, Jun
Li, Yuan
Guo, Lingchuan
Liang, Zhiyong
author_sort Pan, Boju
collection PubMed
description INTRODUCTION: Programmed cell death ligand-1 (PD-L1) expression is a promising biomarker for identifying treatment related to non-small cell lung cancer (NSCLC). Automated image analysis served as an aided PD-L1 scoring tool for pathologists to reduce inter- and intrareader variability. We developed a novel automated tumor proportion scoring (TPS) algorithm, and evaluated the concordance of this image analysis algorithm with pathologist scores. METHODS: We included 230 NSCLC samples prepared and stained using the PD-L1(SP263) and PD-L1(22C3) antibodies separately. The scoring algorithm was based on regional segmentation and cellular detection. We used 30 PD-L1(SP263) slides for algorithm training and validation. RESULTS: Overall, 192 SP263 samples and 117 22C3 samples were amenable to image analysis scoring. Automated image analysis and pathologist scores were highly concordant [intraclass correlation coefficient (ICC) = 0.873 and 0.737]. Concordances at moderate and high cutoff values were better than at low cutoff values significantly. For SP263 and 22C3, the concordances in squamous cell carcinomas were better than adenocarcinomas (SP263 ICC = 0.884 vs 0.783; 22C3 ICC = 0.782 vs 0.500). In addition, our automated immune cell proportion scoring (IPS) scores achieved high positive correlation with the pathologists TPS scores. CONCLUSIONS: The novel automated image analysis scoring algorithm permitted quantitative comparison with existing PD-L1 diagnostic assays and demonstrated effectiveness by combining cellular and regional information for image algorithm training. Meanwhile, the fact that concordances vary in different subtypes of NSCLC samples, which should be considered in algorithm development. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02898-z.
format Online
Article
Text
id pubmed-8185941
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81859412021-06-09 Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer Pan, Boju Kang, Yuxin Jin, Yan Yang, Lin Zheng, Yushuang Cui, Lei Sun, Jian Feng, Jun Li, Yuan Guo, Lingchuan Liang, Zhiyong J Transl Med Research INTRODUCTION: Programmed cell death ligand-1 (PD-L1) expression is a promising biomarker for identifying treatment related to non-small cell lung cancer (NSCLC). Automated image analysis served as an aided PD-L1 scoring tool for pathologists to reduce inter- and intrareader variability. We developed a novel automated tumor proportion scoring (TPS) algorithm, and evaluated the concordance of this image analysis algorithm with pathologist scores. METHODS: We included 230 NSCLC samples prepared and stained using the PD-L1(SP263) and PD-L1(22C3) antibodies separately. The scoring algorithm was based on regional segmentation and cellular detection. We used 30 PD-L1(SP263) slides for algorithm training and validation. RESULTS: Overall, 192 SP263 samples and 117 22C3 samples were amenable to image analysis scoring. Automated image analysis and pathologist scores were highly concordant [intraclass correlation coefficient (ICC) = 0.873 and 0.737]. Concordances at moderate and high cutoff values were better than at low cutoff values significantly. For SP263 and 22C3, the concordances in squamous cell carcinomas were better than adenocarcinomas (SP263 ICC = 0.884 vs 0.783; 22C3 ICC = 0.782 vs 0.500). In addition, our automated immune cell proportion scoring (IPS) scores achieved high positive correlation with the pathologists TPS scores. CONCLUSIONS: The novel automated image analysis scoring algorithm permitted quantitative comparison with existing PD-L1 diagnostic assays and demonstrated effectiveness by combining cellular and regional information for image algorithm training. Meanwhile, the fact that concordances vary in different subtypes of NSCLC samples, which should be considered in algorithm development. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02898-z. BioMed Central 2021-06-07 /pmc/articles/PMC8185941/ /pubmed/34098964 http://dx.doi.org/10.1186/s12967-021-02898-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Pan, Boju
Kang, Yuxin
Jin, Yan
Yang, Lin
Zheng, Yushuang
Cui, Lei
Sun, Jian
Feng, Jun
Li, Yuan
Guo, Lingchuan
Liang, Zhiyong
Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer
title Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer
title_full Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer
title_fullStr Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer
title_full_unstemmed Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer
title_short Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer
title_sort automated tumor proportion scoring for pd-l1 expression based on multistage ensemble strategy in non-small cell lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185941/
https://www.ncbi.nlm.nih.gov/pubmed/34098964
http://dx.doi.org/10.1186/s12967-021-02898-z
work_keys_str_mv AT panboju automatedtumorproportionscoringforpdl1expressionbasedonmultistageensemblestrategyinnonsmallcelllungcancer
AT kangyuxin automatedtumorproportionscoringforpdl1expressionbasedonmultistageensemblestrategyinnonsmallcelllungcancer
AT jinyan automatedtumorproportionscoringforpdl1expressionbasedonmultistageensemblestrategyinnonsmallcelllungcancer
AT yanglin automatedtumorproportionscoringforpdl1expressionbasedonmultistageensemblestrategyinnonsmallcelllungcancer
AT zhengyushuang automatedtumorproportionscoringforpdl1expressionbasedonmultistageensemblestrategyinnonsmallcelllungcancer
AT cuilei automatedtumorproportionscoringforpdl1expressionbasedonmultistageensemblestrategyinnonsmallcelllungcancer
AT sunjian automatedtumorproportionscoringforpdl1expressionbasedonmultistageensemblestrategyinnonsmallcelllungcancer
AT fengjun automatedtumorproportionscoringforpdl1expressionbasedonmultistageensemblestrategyinnonsmallcelllungcancer
AT liyuan automatedtumorproportionscoringforpdl1expressionbasedonmultistageensemblestrategyinnonsmallcelllungcancer
AT guolingchuan automatedtumorproportionscoringforpdl1expressionbasedonmultistageensemblestrategyinnonsmallcelllungcancer
AT liangzhiyong automatedtumorproportionscoringforpdl1expressionbasedonmultistageensemblestrategyinnonsmallcelllungcancer